NSRX vs SCLX

Nasus Pharma Ltd. vs Scilex Holding Company — Valuation Comparison 2026

NSRX

Drug Manufacturers - General
Nasus Pharma Ltd.
Quality
1.9
out of 10
Value Trap
Price
$3.20
Last close
Models
7/13
Active
VS

SCLX

Drug Manufacturers - General
Scilex Holding Company
Quality
4.7
out of 10
Value Trap
44
WARN
Price
$7.21
Last close
Models
5/13
Active

Model-by-Model Comparison

ModelType NSRX Fair ValueNSRX Upside SCLX Fair ValueSCLX Upside
Bayesian DCF Intrinsic $0.85 -73.5% $33.36 +463.5%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $2.27 -24.8%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $13.06 +81.2%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NSRX vs SCLX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NSRX vs SCLX — Which Stock Is More Undervalued?

SCLX scores higher with a 4.7/10 quality rating vs NSRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nasus Pharma Ltd. (NSRX) and Scilex Holding Company (SCLX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NSRX currently trades at $3.20 with a QOC of 1.9/10, while SCLX trades at $7.21 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).